Sorafenib and TRC105 in Hepatocellular Cancer

NCT01306058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Hepatoma
Liver Neoplasms
Adenoma, Liver Cell
Carcinoma, Hepatocellular
Liver Neoplasms, Experimental

Interventions

DRUG: TRC 105
DRUG: Sorafenib

Sponsor

National Cancer Institute (NCI)